The board of directors of Pfizer Inc (NYSE:PFE) declared on Thursday its dividend of USD0.34 on its common stock for the Q4 2018.
Shareholders of record at the close of business on 9 November 2018 will receive the dividend payment on 3 December 2018.
In addition, the cash dividend will be the company's 320th consecutive quarterly dividend.
According to the company, it is engaged in the discovery, development and manufacture of health care products, including medicines and vaccines as well as many of the world's best-known consumer health care products.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses